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Abstract
Background: Current health economic evaluation guidelines mainly concentrate on immediate health gains and
cost savings for the individual involved in the intervention. However, it has been argued that these guidelines are
too narrow to capture the full impact of vaccination in low and middle income countries. The inclusion of broader
economic impact of vaccines (BEIV) has therefore been proposed. Some examples of these are productivity-related
gains, macro-economic impact, and different externalities. Despite their potency, the extent to which such benefits
can and should be incorporated into economic evaluations of vaccination is still unclear. This mixed methods study
aims to assess the relevance of BEIV to different stakeholders involved in the vaccine introduction decision making
process.
Methods: In this mixed method study an internet based survey was sent to attendees of the New and
Underutilized Vaccines Initiative meeting in Montreux, Switzerland in 2011. Additionally, semi-structured interviews
of 15 minutes each were conducted during the meeting. Study participants included decision makers, experts and
funders of vaccines and immunization programs in low and middle income countries. Descriptive analysis of the
survey, along with identification of common themes and factors extracted from the interviews and open survey
questions was undertaken.
Results: Evidence on macro-economic impact, burden of disease and ecological effects were perceived as being
most valuable towards aiding decision making for vaccine introduction by the 26 survey respondents. The 14
interviewees highlighted the importance of burden of disease and different types of indirect effects. Furthermore,
some new interpretations of BEIVs were discussed, such as the potential negative impact of wastage during
immunization programs and the idea of using vaccines as a platform for delivering other types of health
interventions. Interviewees also highlighted the importance of using a broader perspective in connection to
measuring economic impacts, particularly when attempting to derive the value of newer, more expensive vaccines.
Conclusion: According to participants, BEIVs were seen as being equally important as traditional outcome
measures used in cost-effectiveness analyses. Such insight can be used to shape research agendas within this field
and to eventually create broader, more inclusive practical guidelines for economic evaluations of vaccines.
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Background
It is estimated that in 2013, 6.3 million children worldwide
died before turning five, equal to almost 17.000 children
every day [1]. The leading causes of under-five mortality
among children have been found to be pneumonia, other
acute respiratory infections, and childhood diarrhea [1,2].
Despite a commendable average reduction of 49% from
1990 to 2013 [1], the decrease in current mortality rate will
need to be quadrupled in order to reach the Millennium
Development Goal of a two-thirds reduction in child mor-
tality by 2015 [2]. It is estimated that an extra 4.2 million
lives could be saved by ensuring access to comprehensive
vaccine coverage [3]. However, low and middle income
countries (LMICs) and international donors alike only have
limited resources at their disposal. Hence, governments and
donors have to trade off purchasing vaccines against other
health care investment decisions [4,5]. Economic tools such
as cost-benefit (CBA) and cost-effectiveness analysis (CEA)
have the potential to strengthen the use of evidence in such
a decision making context [6], hence creating a more trans-
parent framework for vaccine introduction. Vaccine intro-
duction can be interpreted as the addition of a vaccine to
the Expanded Program on Immunization (EPI program),
the introduction of a new product formulation that was
already part of the program, a new combination vaccine, or
a new route of administration for an already covered vac-
cine [7].
One of the key issues during vaccine introduction, be-
sides issues related to the disease and the strength of the
immunization program and the health system, is the vac-
cine itself in terms of safety, efficacy and the economic
and financial consequences of introducing the vaccine [7].
Several guidelines on economic evaluations of vaccines
have been published by research groups and international
organizations to strengthen evidence based decision mak-
ing during vaccine introduction [8-12]. The core compo-
nents of these guidelines revolve around estimating the
costs and benefits of vaccines and vaccination programs.
Benefit components traditionally include health care cost
savings or improvements in life expectancy and quality of
life. Indirect benefits realized by caregivers and the greater
community and/or effectiveness of the vaccine, as part of
a larger program, are generally not included in these
guidelines [13].
A report developed for the World Bank’s Human Devel-
opment Network (Health, Nutrition and Population Family
series) suggests that policy makers do not base their deci-
sion solely on the CEA results currently prescribed due to a
lack of transparency and inability to factor in country spe-
cific contextual factors [4]. Moreover, it has been argued
that the use of CEA alone may be too narrow to capture
the overall impact of vaccination [14-18] and other child
health programs [19]. In line with this report several initia-
tives, such as the Pan American Health Organization’s
(PAHO) ProVac Initiative in Latin America [6,20],
strengthen the process of national decision making by
providing better infrastructure and tools for economic
analysis, including training, data collection and analysis
and general advocacy for the use of economic evidence in
decision making [6]. Their program ProVac trains national
teams to develop policy briefs using a framework with
technical, financial, operational and social criteria.
Recent reviews of the broader economic impact of vac-
cination (BEIVs) have identified several domains that are
not adequately captured by traditional metrics such as mor-
bidity, mortality and generic health utility measures such as
Disability Adjusted Life Years (DALY) and Quality Ad-
justed Life years (QALY) (see Table 1) [4,14,16,19,21-28].
However, some of the broader domains discussed (e.g.
behavior-related productivity gains), are based on theoret-
ical concepts and have not been subject to adequate em-
pirical quantification. It is therefore important to assess
the relevance of including some of these broader eco-
nomic considerations in economic evaluation studies for
various stakeholders, prior to their inclusion in research
and practical guidelines. Hence, the goal of this study is to
gauge the importance of the various BEIVs from a stake-
holder perspective, and clarify the extent to which BEIVs
can and should be incorporated into the guidelines for
economic evaluations of vaccines to support policymakers
and external funders in making decisions on vaccine
introduction.
Methods
Our study utilized a mixed method triangulation conver-
gence model design [29]. This design allowed for simul-
taneous collection of both quantitative and qualitative
data but also permitted separate analysis of the two com-
ponents prior to comparing their respective results. The
rationale for choosing this approach was to allow our
qualitative findings to elucidate the quantitative data [29].
The qualitative component consisted of face-to-face inter-
views (further referred to as interviews with interviewees)
and the quantitative component involved the use of an
internet based survey (further referred to as survey with
respondents). Both interviews and survey were concur-
rently conducted among the participants of the New and
Underutilized Vaccines Initiative (NUVI) meeting in
Montreux (Switzerland) in May 2011. This meeting was
selected because of good representation from all major
stakeholders involved in vaccine introduction. A wide
range of stakeholder groups were represented including
donor programs such as Global Alliance for Vaccines and
Immunization (GAVI alliance) and the Bill and Melinda
Gates Foundation, international organizations such as
United Nations International Children’s Emergency
Fund (UNICEF) and World Health Organization
(WHO), pharmaceutical companies, research institutes,
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national managers for the EPI program, and other
government or non-government (PATH, AMP, etc.)
representatives.
Ethical clearance
According to the Maastricht Ethical Review Committee
(METC) “no ethical approval was required as the study
is not concerned with medical research”.
Quantitative data collection and analysis
An email was sent to the respondents one week prior to
the NUVI meeting inviting them to participate in an on-
line survey consisting of three parts: (i) introductory
questions about the professional background of the re-
spondents and expertise (ii) questions using a 5-point
Likert-scale on the importance of different organizations
involved in the decision making process, types of evi-
dence used and scenarios gauging the importance of
availability of BEIVs for decision making, (iii) three open
questions about the importance of different types of evi-
dence currently used for decision making on vaccine intro-
duction. The different scenarios were based on various
types of effects and outcomes documented in the literature
(see Table 1) [4,14,16,19,21-28]. These types were catego-
rized into five domains, i.e. burden of disease, productivity-
related gains, ecological effects, indirect effects and macro-
economic impact (Additional file 1).
First, among all respondents, a median was calculated
for every identified impact separately. Second, medians
were calculated for every domain by first calculating the
means for every respondent separately per domain. These
means were used to calculate the median per domain
among all respondents. Medians of 5 were regarded as
very important, 4 as important, 3 as more or less import-
ant, 2 as somewhat important and 1 as not important.
The calculated medians per domain were visualized by
using box plots to give insight in their relative importance.
Third, subgroup analysis was conducted to compare
Table 1 Categorized list of the economic impact of vaccination
Category Definition
A. Burden of disease
1. Morbidity Cases averted [14]
2. Mortality Deaths averted [14]
3.Quality of life measures DALYs and QALYs [14,16]
4. Health care cost savings Reduction in cost of health care borne by the public sector or private individuals [16,23]
5. Governmental savings Reduction in overall costs of government expenses. [21]
B. Productivity-related gains [14,22]
1. Care-related productivity
gains
Reduction in lost days of work due to sickness or caring for a sick patient
2. Outcome-related product-
ivity gains
Increased lifetime productivity due to better health improves cognition, educational attainment and physical
strength
3. Behavior-related product-
ivity gains
Economic improvements due to changes in household choices such as fertility and consumption/saving as a result
of improved child health and survival
C. Ecological effects
1. Prevalence of drug
resistance
Vaccination can prevent disease and thus obviate the need for antibiotic use, reducing the prevalence of antibiotic-
resistant strains [14,22]
2. Serotype replacement
effects
After the introduction of vaccine, non-vaccine serotypes may well replace vaccine serotypes, leading to a smaller re-
duction in disease burden over time [24].
3. Herd effect Benefits accruing because vaccination improves outcomes among unvaccinated community members [21]
D. Indirect effects
1.Equity More equal distribution of health outcomes [4,19].
2. Interaction with other
interventions
Events happening during the evaluation period not related to the intervention [4,25].
3. Health resources Impact of vaccine programs on amount of health resources available (time, availability) [25]
4. Priority of interventions Overlooking importance of social determinants of health by focusing on ‘silver bullets’ and ‘mass campaigns’ instead
of adapting interventions to the prevailing culture and socioeconomic conditions, which generate the felt needs.
[23]
E. Macro-economic impact
1. Burden on other sectors Macro-economic effect of vaccines on other sectors during epidemics [26]
2. School absenteeism Amount of schooldays missed due to illness [16,27,28].
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medians per domain from different geographical working
areas (global, low income, middle income) and by institu-
tional affiliation (government, international organization,
research institution). The geographical working areas were
based on the World Bank GDP classification of countries
in 2011 [30].
Qualitative data collection and analysis
Respondents of the quantitative survey were offered the
opportunity to self-select themselves into the interview
sample. Interviewees were also personally recruited by
RH, IvdP, MPVA and MJ during meeting breaks. The
interview questions were exploratory in nature and
based on themes covered in the survey. Interviewees
were first asked to describe the current decision making
process in the country(ies) or region(s) they were re-
sponsible for. Subsequent questions covered the applic-
ability of BEIVs to their jurisdiction; any known
economic evaluation cases wherein evidence alluding to
a BEIV has been included and the methodology utilized
for its measurement; the relevance of BEIVs when ap-
plied to both traditional EPI vaccines and newer, next
generation vaccines (Additional file 2). Representatives
from all relevant stakeholder groups were interviewed by
either one or two interviewers.
The interview transcripts, interviewer notes and an-
swers to the open-ended survey questions were summa-
rized and analyzed by IP using a qualitative data analysis
program (Nvivo). This was done by extracting basic
themes from each of the different sources, using the the-
oretical framework underlying the survey as a reference
point. Per effect, the specific information mentioned in
the interviews was listed and quotes were selected. New
topics were added into the framework if one interviewee
mentioned a topic that was not previously captured. All
authors discussed accuracy of the analyses and consen-
sus was obtained in case of disagreement.
Merging of separate analyses
Survey responses and interview comments were com-
bined for each domain. Interviewee comments were
used to explain results or to elucidate outcomes by giv-
ing practical examples of specific BEIVs.
Results
Out of 140 respondents invited, 26 completed the survey
in full while 11 respondents commenced but did not
complete any of the analyzed open or Likert-scale ques-
tions. Of the 26 surveys included in the final analysis, 10
contained at least one or more questions with a missing
response (see Figure 1). Survey respondents were of an
average age of 45 years (SD 8.34), with an equal gender
split. The average work experience of respondents in the
field of immunization was 14.6 years (SD 10.75). Four
worked exclusively in low income countries (LICs) and
seven in middle income countries (MIC). Fifteen respon-
dents worked in a mixed LMICs environment. In total,
all respondents belonged to one of five stakeholder
groups being represented at the meeting (see Table 2).
Seven interviewees volunteered to be interviewed for
the qualitative portion of our study. A further 7 attendees
agreed to participate after being approached during the
NUVI meeting. Members of all stakeholder groups were
interviewed (see Table 3). All continents, except Australia,
were represented in the qualitative interviews. Specifically,
two interviewees worked exclusively with LICs, six with
MICs and six with LMICs.
Current decision-making process
Survey respondents identified the Ministry of Health,
Ministry of Finance and special expert advisory groups,
such as National Immunization Technical Advisory
140 participants
approached
37 participants
responded
26 participants
included in
analysis
16 participants
without missing
values
103 participants
declined to
participate
11 participants
drop-out
10 participants
with missing
values
Figure 1 Flowchart respondents of survey.
Table 2 Distribution of institutional background (N = 26)
Institutional background N = 26 Percentage (%)
Government 4 15.4%
International organization 12 46.2%
Research institute 5 19.2%
Donor 3 11.5%
Vaccine manufacturer 2 7.7%
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Groups (NITAGs - named by thirteen respondents) [31]
and Inter-agency Coordinating Committees (ICCs -
named by four respondents), as being most important
during the decision making process around new vac-
cines. One interviewee also underlined the increased
role of NITAGs in decision making by providing gov-
ernment with recommendations based on all available
vaccine specific evidence. The decision-making process
has thus become more formal and scientific than before
due to the inclusion of NITAGs. Survey respondents
also cited the importance of local advisory groups
(mostly professional associations). The parliament,
international organizations such as Medicines Sans
Frontier (MSF), UNICEF and WHO were seen as more
or less important (median of 3).
Survey respondents stated that effectiveness data, bur-
den of disease, cost-effectiveness data, overall costs of
immunization program, public sector budget impact and
evidence of vaccine safety were all seen as being very im-
portant considerations for making a well-balanced deci-
sion. Accessibility, applicability, credibility, the availability
of other interventions, and equity/fairness were also worth
considering (medians between 3 and 4) but in the context
of decision making were viewed as being not as important
as the other types of evidence above.
Interviewees stated that the decision-making process
around vaccine implementation in LMICs is quite diverse
per country. According to a non-governmental organization
(NGO) representative working in Africa, most African coun-
tries use data on mortality rates, cases averted and absentee-
ism as the core for decision making. Absenteeism numbers
are collected together with evidence on vaccine coverage in
Brazil as well. No evidence on QALYs or DALYs as an iso-
lated measure is believed to be used for decision making in
most LMICs. In one Asian LIC, evidence on disease burden
(mortality, morbidity and DALYs) and health sector impact
are used to convince the Minister of Finance to invest in
new vaccines. Next to disease burden, impact on productiv-
ity was observed by looking at school attendance or working
days lost. However, no set decision threshold is used. Vac-
cine costs and safety also play a role. For example, the Hu-
man Papillomavirus (HPV) vaccine targets an area of high
disease burden but is also very costly and is therefore not
implemented. Lastly, the importance of “herd effects” was
acknowledged but no explicit mechanisms for their inclu-
sion were declared.
Relative importance of domains
Macro-economic impact, burden of disease and ecological
effects were observed to be the most valuable domains ac-
cording to the quantitative survey (Figure 2). All scored
above four on the Likert-scale, which indicates very im-
portant. Specifically, evidence on herd effects was viewed
as most important, closely followed by governmental cost
savings, deaths averted and burden on other sectors.
Productivity-related gains and indirect effects were seen
to be somewhat valuable. The relatively low Likert-scores
for productivity-related gains can be partly attributed to
the low score for productivity outcomes relating to house-
hold behavior. For the indirect effects domain, the effects
measured were all observed to be somewhat valuable. De-
tailed results providing an account of the importance of
specific effects within each domain follow.
Burden of disease
Overall survey responses and four interviewees asserted the
importance of burden of disease as being the most powerful
evidence type in support of vaccine implementation. Two
Table 3 Background characteristics of interviewees
Gender Continent Area of core interest Stakeholder group
M* Africa Low income country International organization
F South America Middle income country Vaccine manufacturer
M Europe Global International organization
M Europe Middle income country Government
M* Europe Global Research institute
M* North America Global International organization
M* South America Middle income country Research institute
F* Africa Global Donor
M Asia Middle income country Government
F Asia Global Research institute
M Asia Global Donor
M* South America Middle income country International organization
M Asia Low income country Government
F* South America Middle income country Government
*Interviewee completed the survey and volunteered to be interviewed.
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interviewees regarded burden of disease to be the primary
basis for implementation with other evidence types being
included for purposes of balanced appraisals. Another
interviewee expressed that outcomes demonstrating a re-
duction in burden of disease, such as reduction in under-
five mortality, as compelling evidence capable of attracting
further investment by potential funders outside the health
sector. Similarly, evidence on deaths averted was viewed as
being more important than the amount of cases averted.
The fourth interviewee highlighted the general importance
of burden of disease but did not elaborate on its higher
relevance. Three interviewees mentioned the importance of
morbidity together with mortality as they are often used in
CEA studies. However, one interviewee did not consider
morbidity to be a very important outcome as it “only re-
flects reduction in contraction of the disease” (sic).
Survey respondents generally ranked QALYs as being
very important. During the interviews most of the inter-
viewees talked about QALYs or DALYs interchangeably.
Interviewees mentioned that the use of QALYs or DALYs
depends on the country specific availability of such type of
indicators. Measuring them was seen as valuable, but cap-
acity building of local expertise to measure and value
quality of life indicators was also needed. One interviewee
also mentioned the complicated nature of using QALYs
and DALYs in decision making, as the outcomes are diffi-
cult to explain to decision makers not trained in econom-
ics and public health.
Providing evidence on the impact of vaccines on
health care costs was seen as being just as important as
evidence on morbidity. One participant asserted that a
reduction in disease-related health expenditures could
be a possible effect of vaccine implementation. Two in-
terviewees considered budgetary impact to be one of the
main ways of convincing decision makers to invest in
immunization programs, while a third interviewee saw
evidence of vaccine impact on the health care budget as
an aim for conducting CEA research. To underline its
importance, one of the interviewees mentioned that
budget impact analysis was considered to be the most
important type of economic evidence in MICs such as
India and Indonesia.
Governmental cost savings was another factor. The im-
pact of a vaccine on the national budget was mentioned
by one of the survey respondents. Only one interviewee
discussed the importance of impact on the entire govern-
mental budget. He regarded it to be valuable evidence as
ultimately the department for development and planning
and Minister of Finance makes the final decision.
Productivity-related gains
Seven out of fourteen interviewees alluded towards the
possibilities of measuring productivity gains. Only one
interviewee said something about all three types of ef-
fects included within this domain, while the others only
elaborated on outcome-related productivity gains.
Compared with the other types of productivity gains
mentioned in the survey, outcome-related productivity
gains were viewed as being most relevant. One interviewee
reflected on how a polio outbreak in his country also led to
a loss of production over time due to the cognitive impact
of the disease on patients. Importantly, interviewees were
aware of some issues limiting the relevance of outcome-
related productivity gains. Firstly, one interviewee recog-
nized that despite its theoretical validity, the argument that
child immunization could lead to increased productivity
later in life was hardly ever brought up during discussions
with Ministries of Health. Secondly, two other interviewees
acknowledged the added value of such evidence but also
pointed to difficulties in measuring such an effect due to in-
sufficient data. Thirdly, another interviewee only partly
agreed on the applicability of outcome-related productivity
gains as they felt that it could only be used to evaluate
benefits of certain vaccines targeting diseases, such as
Japanese Encephalitis, which leads to some sort of cognitive
damage in a third of the infected children. A further three
Figure 2 Boxplots importance of providing evidence on vaccine related issues per domain.
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interviewees were less convinced about the applicability of
outcome-related productivity gains, stating that these gains
were already implicitly included in the calculation of bene-
fits and that it only provides a parental perspective rather
than a governmental one.
Care related productivity gains were acknowledged by 3
interviewees and further discussed by one of them. This
interviewee mentioned that care-related productivity gains
could be more relevant in the context of high income
countries (HICs) rather than LMICs. For example, the
introduction of the chicken pox (varicella) vaccine in the
United States is primarily based on this effect. The similar
impact is harder to establish in LMICs, as not all parents
work full time and hence will not be absent from work.
Survey results showed that behavior-related productivity
gains were considered to be least valuable for decision
making. One possible explanation cited by an interviewee
is that behavior-related productivity gains are very difficult
to measure. There are also many social and cultural issues
that can confound this relationship. For example: “In
Brazil there is high vaccine coverage and high participa-
tion of women in the job market than next door to Bolivia
with bit lower vaccine coverage and probably much lower
participation in the job market. But then Bolivia’s econ-
omy is not so strong, culturally women’s have another
position in society. Female education is lower in Bolivia,
Types of work for [women] and kind of work is less. Is
that because of vaccines or something else?” (sic).
Ecological effects
The impact of herd immunity on cost-effectiveness was
seen as the most important ecological effect to measure.
This is underlined by the fact that six respondents
named it as a potential BEIV in the open questions. All
three interviewees who discussed herd immunity
thought it was an important ecological externality to
measure in economic evaluations. Two cited the polio
vaccine as an example where herd immunity is consid-
ered during the decision-making process in their
country.
The effect of vaccination on reducing antimicrobial drug
resistance was seen as the next most valuable outcome of
an ecological effect. One survey respondent specified this
effect in the open questions. Although, one interviewee re-
ported that inclusion of the impact of a vaccine on drug
resistance is only valuable in some cases, as in the malaria
vaccine.
Serotype replacement was also deemed important al-
beit accompanied by a negative intonation with respect
to vaccine advocacy. As one interviewee suggested, evi-
dence demonstrating an eventual increase in detected
cases of non-vaccine serotype cases (irrespective of oc-
currence of true replacement) would work against calls
for increased vaccine provision and uptake.
Indirect effects
From the overall survey results, we found that indirect ef-
fects were one of the least important domains. Evidence of
impact on equity, health resource utilization and priority of
interventions were all scored with a median of three. Only
evidence on the possibility of interaction with other inter-
ventions was considered important. However, in the open
questions many respondents referred to different indirect
effects. One interviewee stated that inaccurate calculation
of costs and not accounting for hidden or unanticipated
costs involved with vaccine implementation could be a po-
tential issue.
The interplay between health rights and equity was
also discussed by one interviewee, who stated “When
implementing immunization programs it is very import-
ant to reach the lower socio-economic classes as the lar-
gest health gains can be obtained in this group”.
Positive externalities of vaccination programs in strength-
ening other health services were also mentioned during the
interviews and in the open questions. Nine respondents in-
dicated vaccines as an entry point or platform for providing
a wide range of other public health interventions such as
school-based and maternal health interventions. One inter-
viewee gave some examples on how vaccine programs can
improve health in other areas. “For example, when rotavirus
vaccine was introduced in diarrheal disease surveillance
and monitoring was improved. This had a positive effect on
other disease surveillance in terms of training and educa-
tion of staff in monitoring and evaluation etc.” Another
interviewee also stressed that vaccines are normally not im-
plemented as a single solution but are supported by other
health interventions that target other causes of the disease.
This possibility was also mentioned by three respondents of
the survey.
Moreover, four interviewees saw the possibility of cap-
acity building through education and training for health
care workers. However, one interviewee warned against
rolling out interventions without ensuring availability of
trained personnel as this can create an additional burden
on health care workers.
None of the interviewees or survey respondents thought
investing in vaccines would result in a misdirection of
focus, for example, using cholera vaccines as a quick and
easy fix in place of investing in tackling a more fundamen-
tal health hazard such as clean drinking water and
sanitation.
Macro-economic impact
Survey results showed that the potential burden stemming
from preventable outbreaks of disease on other non-
health sectors of the wider economy is highly relevant in-
formation. The education sector and the effect of school
absenteeism was regarded to be important and could be
one example of a non-health sector in a certain sense.
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However none of the respondent mentioned economic
impact on other sectors in the open questions and only
one interviewee gave examples of the impact that vaccines
may have on other sectors. Examples given were a hepa-
titis A virus and measles outbreak in an Eastern European
country and an outbreak of polio virus, negatively affect-
ing local fruit and vegetable markets.
Nonetheless, both survey respondents and interviewees
reflected on the importance of evidence on school absentee-
ism of children. Two interviewees reported that the impact
of vaccines on absenteeism offers a strong argument in favor
of vaccine implementation, especially in the case of malaria.
Furthermore, one interviewee testified towards a relation-
ship between an NGO financed immunization program and
reduced school absenteeism, eventually resulting in a posi-
tive impact on the overall economy of African countries.
However, another interviewee did not agree with this point
and doubted the validity of such a causal relationship.
Other BEIVs
Interviewees mentioned some other possible positive ef-
fects of vaccination that are not usually discussed. One
is the establishment of wide service network for children
in the region. Another is the overall strengthening of
local health care systems. Certain social goals can also
be framed into becoming good rationales for vaccine up-
take. For example, the HPV vaccine has been introduced
in South America as it reduces mortality of young
women of child-bearing age and hence the likelihood of
orphaned children in the community.
One of the interviewees expressed concern that positive
external are disproportionately measured in economic
evaluation studies. This is a valid criticism considering, as
one interviewee pointed out, that improper disposal of
medical waste generated by the EPI program is a main
issue in Africa. Sometimes used needles can be found on
sites, which can potentially transfer pathogens from sick
to healthy children.
New tools for estimating BEIVs
None of the survey respondents or interviewees were able
to propose new methods of evaluation. However, some in-
terviewees and respondents advised on using some tools
not included in the survey. These include PATH guidelines
on economic evaluation of vaccines, the return on invest-
ment approach informing Ministry of Finance or Planning
Departments on cost-effectiveness of vaccines and evaluat-
ing the effectiveness of vaccines in an individual country
context during implementation. Furthermore, one inter-
viewee mentioned vaccines should be evaluated in relation
with social determinants of health. This idea is rooted in
the belief that children do not die only from vaccine-
preventable diseases but are also exposed to other risk
factors.
Area of core interest
Table 4 illustrates that in general, stakeholders working
in LICs value evidence on burden of disease, ecological
effects and macro-economic impact more highly than
professionals working in MICs. For productivity-related
gains, no differences could be found based on geograph-
ical working area. For the indirect effects, some differ-
ences could be identified between professionals working
within a global context compared to professionals work-
ing in LICs, such as equity principles, which are more
valued in LICs. However, only macro-economic impact
is scored above four by the stakeholders working within
a global context whilst representatives from MICs have
scored ecological effects as a four.
Different stakeholder groups
Table 5 gives an overview of the calculated importance of
each domain specific to stakeholder group. Due to a lack
of data on donors and manufacturers, scores for these
stakeholders were not calculated. Respondents working in
governmental bodies were seen to give higher scores to
burden of disease, ecological effects and macro-economic
impact. A similar trend was observed for respondents
from international organizations and research institutes,
although none of the domains were scored as very import-
ant for the latter group.
Applicability to new versus traditional EPI vaccines
Four interviewees conveyed challenges with regards to
the measurement of BEIVs for newer vaccines. Due to
paucity in data, some interviewees recommended meas-
uring BEIVs in older vaccines as the relevant economic
and clinical data may be unavailable for new vaccines.
Table 4 Median scores per domain by geographical working area of core interest
Domains Low income countries Middle income countries Global
N Score N Score N Score
Burden of disease 4 4.7 7 3.6 14 3.9
Productivity related gains 3 3.25 7 3.25 10 3.25
Ecological effects 3 5.00 7 4.00 13 3.66
Indirect effects 4 3.50 5 3.50 11 3.25
Macro-economic impact 4 4.50 7 3.50 12 4.25
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There are also some inherent problems related to the
type of diseases being targeted by newer vaccines. For
example, benefits from the HPV and Hepatitis B Virus
vaccines only occur much later in life. This increases the
complexity of models involved and technical expertise
required. In the case of rotavirus and pneumonia, reduc-
tions in mortality can only be observed at a global level
as the disease is still widely prevalent at an individual or
local level and utilizes many of the same resources (i.e
health care workers, antibiotics). This factor affirms the
relevance of including BEIVs in conveying the true value
of new vaccines. Additionally, traditional EPI vaccines
were also viewed as having a greater societal impact as
they targeted diseases with greater incidence rates and
which affected a greater proportion of children.
Discussion
This study offers unique insight into the reasoning and
justification employed by decision makers, funders and ex-
perts in the field of vaccine introduction.
According to respondents, the Ministries of Health, Fi-
nance and NITAGs play a crucial role in the current deci-
sion making process around new vaccine introductions.
Although the numbers of NITAGs globally have been
growing, the level of expertise in health economics has
been limited and lacking in most LMICs [31]. Hence, expli-
cit guidance on the inclusion of BEIVs by international or-
ganizations such as WHO would be most timely and well
received.
Our study results indicate that evidence on burden of dis-
ease, safety and cost-effectiveness is regarded as most im-
portant for vaccine introduction decisions. This is in
contrast to findings from another qualitative study which
reported that only burden of disease evidence, and on occa-
sion affordability and safety, was essential for immunization
program decision making in seven LMICs [32]. More im-
portantly, our study affirms that BEIVs belonging to eco-
logical effects and macro-economic impact domains are
considered to be equally as important as the more trad-
itional outcome measures. Indirect effects and care-related
productivity gains were considered less important to include
in economic evaluation. Quite similarly, Burchett et al. [32]
also reported that serotype replacement effects and, impact
on non-health outcomes were rarely mentioned whereas
equity considerations were only acknowledged in South
Africa. Although productivity gains have often been cited in
other studies [14,15,18,22,33], one explanation why this do-
main ranks lower on some studies [17] could be its relatively
high importance to economists rather than clinicians and
public sector officials who may be less familiar with its
causal relationship. Cultural and contextual differences
could be another possible explanation [4]. Indeed we
observe that respondents dealing in an LIC context and rep-
resentatives of government bodies tend to give higher im-
portance to BEIVs than other stakeholders.
Considerations not covered by the survey were also
brought up by interviewees. For example, the potential
negative impact of wastage during immunization pro-
grams or the idea of using vaccines as a platform for
providing other health interventions. The concept of
combining vaccination with other interventions is not
new [23]. However it remains difficult to translate the
potential benefits of this synergistic effect into economic
terms. Furthermore, interviewees highlighted the im-
portance of using a broader perspective particularly
when deriving the value of newer and costlier vaccines.
This can be explained by the substantially higher list
prices for new developed vaccines [34]. Several inter-
viewees also reported the existence of different audi-
ences. This finding underlines the necessity for flexible
guidelines and the importance of combining different
evaluation techniques to accommodate different needs
and evaluation perspectives.
There are also several limitations to our study worth
highlighting. Firstly, as most of the NUVI participants
are actively involved in vaccine advocacy at a global as
well as country level, the results may reflect biased view-
points in favor of promoting the wider benefits of vac-
cines. Since this study was exploratory in nature, it was
important to select a group that was actively engaged in
decision making. It may be useful to conduct the survey
within a more neutral group in the future. Secondly, the
study suffered from a low response rate. Only 26 out of
140 respondents participated, which could be explained
by the estimated 30 minute completion time. As a result
none of the subgroup analyses performed were statisti-
cally significant. Future versions should attempt to be
shorter. Offering rewards to attract participants could
Table 5 Median scores per domain by institutional background
Domains Government International organization Research institute
N Score N Score N Score
Burden of disease 4 4.50 12 4.10 5 3.60
Productivity-related gains 4 3.88 9 3.25 5 3.00
Ecological effects 3 4.33 11 4.00 5 3.67
Indirect effects 4 3.25 10 3.38 4 3.25
Macro-economic impact 4 4.25 11 4.38 5 3.50
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also be considered. Furthermore, the data collection could
be organized in another setting. For example, the survey
could be performed in workshop setting with direct feed-
back to the audience. Thirdly, the placement of the different
types of impacts in the framework can be discussed. This is
especially the case with school absenteeism which can also
be placed under productivity-related gains and governmen-
tal savings which can be interpreted as a macro-economic
impact. A separate analysis was performed to give insight in
the outcomes for this alternative framework. It was found
it would not change the results except for the macro-
economic impact, which would be valued as even more
important. Fourthly, using a Likert-scale has several meth-
odological disadvantages [35]. These can be overcome by
using a discrete choice experiment which would allow for
a more explicit analysis of trade-offs between the various
BEIVs and might offer greater discriminatory power than
Likert-scales [36]. Finally, the qualitative part was sup-
posed to add a layer on top of the survey findings, by pro-
viding illustrative anecdotal experiences and thoughts on
feasibility of including BEIV in economic evaluation studies.
However, it was difficult to conduct a sound comparison of
the qualitative and quantitative part of the research, because
not all interviewees filled out the survey. This may have re-
sulted in recall bias as participants that contributed to both
were already familiar with the different types of BEIVs out-
lined in the survey. To get more insight in this bias we
checked for overrepresentation of both components in the
results. No indications of this were to be found.
Conclusion
Notwithstanding the limitations of this study, the unique-
ness of this project should be considered as the study re-
sults will contribute to a better understanding by decision
and policy makers regarding the usefulness of BEIVs infor-
mation for vaccine introduction decisions at national level.
Furthermore, these insights can also be used to shape up-
coming research agendas in this field to facilitate creation
of more comprehensive guidelines on economic evalua-
tions of vaccines. However, several country-level studies
should be conducted to test the proposed BEIVs on their
ability to address the needs of different stakeholders and
applicability to inform different audiences.
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